Molecular Mechanisms in Heart Failure : The Role of Syndecan-4 in Development of Myocardial Hypertrophy and Heart Failure by Finsen, Alexandra Vanessa
Institute for Experimental Medical Research 
Center for Heart Failure Research 
Ullevål University Hospital 
University of Oslo 
 
 
Molecular Mechanisms in Heart Failure 
 
 
The Role of Syndecan-4 in Development  
of Myocardial Hypertrophy and  
Heart Failure 
 
Alexandra Vanessa Finsen 
 
 
Oslo 2008 
 
 
 
© Alexandra Vanessa Finsen, 2008 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 640 
ISBN 978-82-8072-898-2 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AiT e-dit AS, Oslo, 2008.   
Produced in co-operation with Unipub AS.  
The thesis is produced by Unipub AS merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
Unipub AS is owned by  
The University Foundation for Student Life (SiO)
 3
Contents 
Acknowledgements          5 
List of papers           6 
Selected abbreviations         7 
Introduction           8 
 Congestive heart failure        8 
  Definition         8 
  Prevalence         8 
  Causes          8 
  Early cardiac responses       8 
Myocardial remodeling       9 
Induction of myocardial hypertrophy              10 
Treatment strategies                 10 
Prognosis                  11 
Aims of the study                   12 
Summary of results                   13 
 Paper I                    13 
 Paper II                   13 
 Paper III                   13 
 Paper IV                   14 
Methodological considerations                 15 
 Animal models                  15 
 Echocardiography                  16 
Histology and immunohistochemistry               16 
Transmission electron microscopy                17 
Array screening                  17 
RT-qPCR                   17 
Northern and Western techniques                18 
Measurement of infarct area                 18 
Cultured neonatal cardiomyocytes and fibroblasts              18 
Overlay techniques                  19 
Pull down techniques                  19 
Peptide synthesis and use of blocking peptides              20 
 4
Generation of genetically modified mice               20 
Measuring Ca2+ ATPase content                20 
Cardiomyocyte contraction measurements               21 
Ca2+ imaging                   21 
Voltage clamp techniques                 21 
In vivo electrocardiogram recordings               22 
In vivo isoproterenol infusion                22 
Discussion                    23  
 Animal models of human heart disease               23 
Role of syndecan-4 in pathological hypertrophy and heart failure            24 
 Syndecan-4                  24 
  Syndecan-4 expression in CHF               25 
  Potential mechanisms of action               25 
  Potential direct effect of syndecan-4 on the regulation of the    
  calcineurin – NFAT pathway                          27 
  Syndecan-4 as a new target for therapy              28 
Role of SERCA2 in heart failure                29 
Conclusions                    31 
Errata                                                                                                                                  32 
Reference List                   33 
 
 
 
 
 
 
 
 
 
 
 
 
 5
Acknowledgements 
The work for this thesis was carried out at the Institute for Experimental Medical 
Research at Ullevål University Hospital. It was made possible by the encouraging and wise 
guidance by my supervisor Professor Geir Christensen. I am especially grateful for his prompt 
feedback and relentless interest in the project.  
I have appreciated working with skilful colleagues, and want to thank my co-authors 
Per Reidar Woldbæk, Jian Li, Jiaping Wu, Torstein Lyberg, Theis Tønnessen, Ivar Sjaastad, 
Even K. Østli, Marianne Lyngra, Hilde O. Jarstadmarken, Cathrine Rein Carlson, Ståle 
Nygård, Sarah A. Wilcox-Adelman, Paul F. Goetinck, Srdjan Djurovic, Kristin B. Andersson, 
Yibin Wang, Ju Chen, Kenneth R. Chien, Ole M. Sejersted, Jon Arne K. Birkeland, William 
E. Louch and Jeffery D. Molkentin for valuable contributions. 
I am most grateful to Bjørg Austbø, Unni Lie Henriksen, Annlaug Ødegård, Geir 
Florholmen, Almira Karahasan, Lisbeth H. Winer, Kristin Arnkværn, Pimthanya W Drågen 
and Ulla H. Enger for invaluable biochemical assistance. I highly appreciate the technical 
assistance received from Tævje A. Strømme, Paul F. Gjerpe and Roy Trondsen with 
illustrations and solving numerous computer problems. I would also like to thank Morten 
Eriksen, Carsten Lund, Siv Leng Tran, Siv Rong Tran, Ann-Kristin Josefsen and Line Solberg 
for expert animal care. Furthermore, I would like to acknowledge Ole M. Sejersted, Anne-
Gunn T. Nilsen and Jo-Ann F. Larsen in the administrative staff, for providing good working 
facilities. I would also especially like to thank each and everyone at the institute for making it 
a friendly and fun place to work, and not least Elisabeth Leistad for first introducing me to the 
institute. 
The contributions from Tove Noren, Kahsai Beraki and Aud Svindland are also highly 
appreciated. 
Finally, I appreciate the interest family and friends have shown in my work. I am 
especially grateful to my partner Robin for his encouragement and patience. 
Financial support was provided by the Norwegian Research council, Anders Jahres 
Fund for Promotion of Science, Rakel and Otto Kr. Bruun’s Fund and the Ullevål University 
Hospital Fund. 
 
 
 
 
 6
List of papers 
The thesis is based on the following papers, which are referred to by their Roman numerals: 
 
I. Alexandra Vanessa Finsen, Per Reidar Woldbæk, Jian Li, Jiaping Wu, 
Torstein Lyberg, Theis Tønnessen, Geir Christensen. Increased syndecan 
expression following myocardial infarction indicates a role in cardiac remodeling. 
Physiol Genomics 16: 301-308, 2004. 
II. Alexandra Vanessa Finsen, Geir Christensen, Ivar Sjaastad. 
Echocardiographic parameters discriminating myocardial infarction with 
pulmonary congestion from myocardial infarction without congestion in the 
mouse. J Appl Physiol 98: 680 - 689, 2005. 
III. Alexandra Vanessa Finsen, Even K. Østli, Marianne Lyngra, Ivar Sjaastad, 
Hilde O. Jarstadmarken, Ståle Nygård, Sarah A. Wilcox-Adelman, Paul F. 
Goetinck, Torstein Lyberg, Theis Tønnessen, Srdjan Djurovic, Cathrine R. 
Carlson, Geir Christensen. Syndecan-4 is essential for activation of the 
calcineurin-NFAT pathway and development of concentric myocardial 
hypertrophy. 
IV. Kristin B. Andersson, Jon Arne K. Birkeland, Alexandra Vanessa Finsen, 
William E. Louch, Ivar Sjaastad, Yibin Wang, Ju Chen, Jeffery D. Molkentin, 
Kenneth R. Chien, Ole M. Sejersted, Geir Christensen. Moderate heart 
dysfunction in mice with inducible cardiomyocyte-specific deletion of Serca2: A 
role for SR-independent mechanisms 
 
 
 
 
 
 
 
 
 
 
 7
Selected abbreviations 
BNP  B-type natriuretic peptide 
Ca2+  Free calcium ions 
CaM  Calmodulin 
CHF  Congestive heart failure 
ECM  Extra-cellular matrix 
FGF-2  Basic fibroblast growth factor 
FS  Fractional shortening 
HGF  Hepatocyte growth factor 
IL-  Interleukin- 
LIF  Leukemia inhibitory factor 
LV  Left ventricle 
LVEDP Left ventricular end-diastolic pressure 
MAPK Mitogen-activated protein kinase 
MI  Myocardial infarction 
MInf  Myocardial infarction without congestive failure 
NCX  Na+- Ca2+ exchanger 
NFAT  Nucleor factor of activated T-cells 
PKC  Protein kinase C 
PIP2  Phospatidylinositol-4,5 biphosphate 
PLB  Phospholamban 
PP  Protein phosphatase 
RT-qPCR Real time quantitative poly chain reaction 
SERCA2 Sarco(endo)plasmatic reticulum Ca2+-ATPase, isoform 2 
Sham  Animals subjected to operative procedure except ligation of left coraonary 
artery or banding of aorta 
siRNA  Silencing RNA 
SR  Sarcoplasmic reticulum 
TNF- Tumor necrosis factor-  
VEGF  Vascular endothelial growth factor 
VSMC Vascular smooth muscle cells 
WT Wild-type 
 
 8
Introduction 
 
Congestive heart failure 
Definition 
Congestive heart failure (CHF) can be defined as a syndrome in which the heart is unable to 
pump sufficient blood to meet the requirements of the peripheral organs in terms of oxygen 
and cell nutrients at rest and during effort, alternatively only at abnormally elevated diastolic 
pressures or volumes1. This syndrome is normally characterized by the manifestations of 
intravascular and interstitial volume overload (shortness of breath and edema) and/or signs of 
inadequate tissue perfusion (fatigue, poor exercise tolerance and renal failure).  
 
Prevalence 
The prevalence of CHF is increasing dramatically throughout the world, despite an overall 
decline in age adjusted mortality from coronary artery disease (CAD) in developed countries2-
4, 4, 5. This trend primarily reflects the strong association between CHF and the rising 
proportion of elderly people, which have the highest incidence of coronary artery disease and 
hypertension2. There is also a rising prevalence of hypertension, dyslipidemia and diabetes in 
the industrialized countries. CHF is already the most costly medical illness in the United 
States6, and therefore the possible socioeconomic impact of a future CHF epidemic is truly 
alarming.  
 
Causes 
The causes of CHF may be impaired myocardial contractility (i.e. systolic contractility), 
impaired myocardial relaxation or increased ventricular stiffness (i.e. diastolic dysfunction), 
chronic pressure or volume overload, or other disease states in which the capacity of the heart 
is exceeded (e.g. anemia, thyrotoxicosis). Any condition causing myocyte death, myocyte 
dysfunction or ventricular remodeling, or a combination of these, can induce heart failure. In 
developed countries CHF is often a long-term outcome of diseases such as CAD, 
hypertension, valvular disease, myocarditis or idiopathic dilated cardiomyopathy.  
 
Early cardiac responses 
Initially the heart responds with short term adaptive mechanisms consisting of (1) the Frank-
Sterling mechanism, whereby an increased preload helps to sustain cardiac performance; (2) 
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activation of neurohumoral systems, including release of  norepinephrin which augments 
myocardial contractility, and activation of the renin-angiotensin-aldosterone system that acts 
to maintain arterial pressure and perfusion of vital organs; and (3) myocardial remodeling 
with or without  cardiac chamber dilatation, in which myocardial contractile mass is 
increased7. 
 
Myocardial remodeling   
If the initial adaptive mechanisms of the heart are insufficient or the magnitude of the 
overload increases further, regardless of the initial cause, a relentless deterioration of cardiac 
structure and function ensues. This so called chronic myocardial remodeling is characterized 
by myocyte loss due to both necrosis and apoptosis, hypertrophy of individual myocytes, re-
expression of fetal genes and changes in quantity and quality of the extra-cellular matrix 
(ECM)7.  
In addition to causing myocardial remodeling, hemodynamic stress often causes a 
decrease in the intrinsic myocyte contractility. There is increasing evidence that disturbances 
in Ca2+ handling play a central role in the disturbed contractile function observed in heart 
failure, because Ca2+ has an important role in regulating myocardial contraction and 
relaxation8-10. Myocardium from patients with end-stage heart failure display abnormal 
prolongation of the action potential and impaired relaxation. These alterations in electrical and 
contractile properties are associated with a prolonged elevation of the intracellular Ca2+ 
transient during relaxation. Intracellular Ca2+ transients in failing myocytes demonstrate a 
blunted rise with depolarization, reflecting slower delivery of Ca2+ to the contractile 
apparatus, and a slower rate of fall during repolarization. These abnormalities could explain 
both systolic and diastolic dysfunction.    
Myocardial remodeling always comprises changes in mass, volume, shape or 
composition of the left ventricle, in order to maintain or return systolic stress to normal limits. 
Left ventricular mass is increased approximately equally in response to both pressure- and 
volume-overload11. There is a substantial increase in wall thickness in pressure-overloaded 
ventricles, but only a mild or no increase in the volume-overloaded ventricle. In the volume-
overloaded model the increase in wall thickness is only sufficient to counterbalance the 
increase in left ventricular radius. However, the ratio of wall thickness to radius is 
substantially increased in pressure-overload. Thus, when the primary stimulus is pressure 
overload, a parallel replication of myofibrils and thickening of individual myocytes, or so 
called concentric hypertrophy, is seen. On the other hand, volume overload results in 
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increased diastolic wall stress which subsequently causes replication of sarcomeres in series, 
elongation of myocytes and ventricular dilatation, also called eccentric hypertrophy. 
 
Induction of myocardial hypertrophy 
Hemodynamic overload causes activation of growth factors present in the fetal heart but 
dormant in the normal adult heart, and these are responsible for stimulating myocyte 
hypertrophy and regulating the synthesis and degradation of the ECM7. Intracellular signaling 
pathways that have been implicated in the induction of cardiac hypertrophy include the Gq 
subunit of heterotrimeric G proteins, the small GTP binding proteins Ras and Rac, the three 
main branches of the mitogen-activated protein kinase (MAPK) cascades, protein kinase C 
(PKC) isoforms and the calcineurin-NFAT pathway. The calcium/calmodulin-dependent 
protein phosphatase calcineurin is an especially effective inducer of hypertrophy and has been 
shown to be necessary and sufficient for cardiac growth in response to pathological, but not 
physiological stimuli12, 13. Importantly, the calcineurin-NFAT pathway has been shown to 
interact with both the PKC and MAPK pathways, in order to coordinate the hypertrophic 
response14, 15.  
Identification of mechanical stress-sensing molecules mediating the extra-cellular 
stimuli to the appropriate intracellular signalling pathways is one of the most important tasks 
in cardiovascular biology today. As mechanical stress is normally distributed to cells through 
the ECM, transduction of the mechanical stimuli may involve molecules that bind the ECM to 
the cytoskeleton, but exactly which molecules these are is still unknown. The Z-disc proteins 
have been proposed to be an essential part of the mechanical stretch sensing apparatus in 
cardiomyocytes16. Z-discs are multiprotein complexes with a unique position at the interface 
of the sarcoplasmic reticulum, cytoskeleton, contractile apparatus and sarcolemma, and play 
pivotal roles in sarcomeric assembly and organization17. The Z-disc proteins are thought not 
only to function as a physical anchor for myofilament and cytoskeletal proteins, but also as a 
pivot for reception, transduction and transmission of mechanical and biochemical signals. 
 
Treatment strategies 
The understanding of the underlying pathofysiology and the treatment strategies for heart 
failure have changed considerably with time. Approximately 50 years ago patients were 
treated with diuretics, vasodilators and inotropic drugs on the basis of the cardiorenal and 
cardiocirculatory models of heart failure. Although alleviating edema and improving cardiac 
hemodynamics and function, this kind of treatment did not succeed in improving long-term 
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survival18, 19. However, with time one realized that the pathophysiological processes involved 
in CHF also have effects on cardiovascular reflexes and systemic organ perfusion and 
function, which in turn stimulate compensatory responses including the renin-angiotensin-
aldosterone, sympathetic and natriuretic peptide systems20. Thus the neurohormonal 
hypothesis of heart failure was established, and subsequent treatment with angiotensin-
converting enzyme inhibitors, aldosterone antogonists and -blockers has improved CHF 
patients’ morbidity and mortality to a certain degree21-25. 
 
Prognosis  
Despite recent improvements in treatment strategies, CHF still carries a poor prognosis 
comparable to that of malignant disease26. CHF carries a shorter life expectancy for men than 
women, and its prognosis is worse in elderly subjects of both sexes. Only 35% of men and 
50% of women are alive 5 years after developing CHF26-28. Mortality rates are also higher in 
those with low left ventricular ejection fraction and underlying coronary artery disease. 
Because of its high prevalence and morbidity, the management of CHF has vast 
socioeconomic implications. Much still remains to be unraveled with regard to underlying 
molecular mechanisms in order to develop more effective treatment strategies that will 
substantially affect morbidity and mortality. 
 
 
Figure 1. Kaplan-Meier curves for all-cause mortality in CHARM, standardized to median risk and shown by 
sex. Modified from29 and used with permission. 
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Aims of the study 
 
The main aim of the thesis was to study underlying molecular mechanisms contributing to 
development of pathological hypertrophy and heart failure. 
 
The specific aims of the separate studies were to: 
Paper I: 
Identify essential genes with altered expression in the early phase of cardiac 
            remodeling. 
Paper II: 
Identify parameters describing systolic and diastolic function in mice after MI that 
reliably discriminate MI with pulmonary congestion from MI without congestion. 
Paper III: 
To study whether lack of syndecan-4 affects cardiac structure and function before and 
after induction of concentric hypertrophy and to study the interaction between 
syndecan-4 and intracellular signaling cascades.  
Paper IV: 
To explore the cardiac responses to loss of SERCA2 protein in the postnatal 
mammalian heart. 
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Summary of results 
 
Paper I: 
cDNA filter array screening was performed on noninfarcted LV tissue from mice subjected to 
MI and compared to sham-operated mice. As many as 43% of upregulated genes, and 80% of 
induced genes could be related to the ECM.  BMP-1, which is known to process procollagen 
into mature collagen and probiglycan into biglycan, demonstrated increased expression. 
Furthermore, we identified a subset of interacting genes with increased expression following 
MI, including syndecan1-4, Wilms tumor protein 1, fibronectin, collagen 6A and fibroblast 
growth factor receptor 1. 
 
Paper II: 
Mice subjected to ligation of the left coronary artery were characterized by means of 
echocardiography and LV catheterization in order to establish non-invasive parameters that 
reliably discriminate between MI-mice with and without CHF. We found that left atrial 
diameter and an infarct >40% of total LV circumference measured in two-dimensional long 
axis distinguished MI-mice with and without CHF on both an average and an individual basis. 
Mean maximum rate of rise of LV pressure, LV fractional shortening (LVFS), posterior wall 
shortening velocity and mitral flow deceleration velocity distinguished MI-mice with CHF 
from those without on a general basis. LV end diastolic pressure (LVEDP) and maximum rate 
of decline in LV pressure were only able to distinguish mice with CHF from Sham on an 
average basis. 
 
Paper III: 
Cardiac structure and function of syndecan-4-/- mice were characterized before and after 
induction of concentric hypertrophy. Histology and immunohistochemistry showed normal 
deposition of collagen, but slightly decreased cellular cohesivity in syndecan-4-/- mice. 
Transmission electron microscopy revealed a 31% increase in the number of mitochondria 
and irregular widening of the Z-discs in syndecan-4-/- mice. However, syndecan-4-/- mice had 
normal cardiac function at physiological conditions. Following banding of the ascending 
aorta, syndecan-4-/- mice showed no development of concentric hypertrophy, and a 
significantly lower expression of the hypertrophic marker -skeletal actin as compared to WT. 
There was also a specific inhibition of the calcineurin-NFAT pathway in syndecan-4-/- mice 
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during pressure overload. Moreover, syndecan-4 was found to associate with the catalytic 
subunit of calcineurin (calcineurin A). The binding domain of calcineurin A was mapped to 
the V-region of syndecan-4, and the syndecan-4 binding domain to the autoinhibitory domain 
in calcineurin A. Finally, a cell permeable syndecan-4 derived peptide was able to inhibit the 
calcineurin-NFAT pathway and increase the phosphorylation level of NFAT. 
  
Paper IV: 
A genetically modified mouse allowing time-specific Serca2 deletion in cardiomyocytes 
induced by tamoxifen was generated. Four weeks after tamoxifen injection, SERCA2a protein 
level was <5% of control in the myocardium and undetectable in cardiomyocytes. 
Surprisingly, cardiac function was largely preserved at this time (cardiac output 80% of 
controls), and no myocardial hypertrophy was observed. Importantly, the Ca2+ influx through 
the L-type Ca2+ channel and extrusion of Ca2+ through the sodium calcium exchanger, as well 
as myafilament responsiveness were both enhanced, maintaining cardiac contractility.  
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Methodological considerations 
Animal models 
Using mice as experimental animals has several benefits in that they are small, cheap, well 
characterized and possible to modify genetically. On the other hand there are many different 
strains of mice which vary to a certain degree with regard to anatomy and physiology, and 
mice can be both in-bred and out-bred. In Paper I we used Balb-C mice which are albino. The 
use of albino animals in experiments has been criticized especially when used in 
neuropsychiatric research, because of the animals’ reduced hearing and eyesight. However, 
these aberrations would not seem as important in studies of cardiac function. Apart from 
Balb-C, only C57-Black 6 mice and genetically modified animals on a C57-Black 6 
background were used. Both strains are in-bred, reducing the genetic variability to a 
minimum. C57-Black-6 mice do have increased susceptibility for developing atherosclerosis 
though, which could potentially influence cardiac function. This does however only start to 
manifest itself at a much more advanced age than what was examined in these studies. 
The animals were anesthetized with propofol and isoflurane in order to minimize 
cardiac depression. Any kind of anesthesia will affect cardiac function to a certain degree, 
leaving the conditions under which the examination is carried out somewhat un-physiological. 
However, by standardizing and optimizing the anetehesia as much as possible, one is at least 
able to look at relative differences between groups. 
The primary operations consisting of ligation of the left coronary artery and banding 
of the ascending aorta, are described in detail in Paper III and elsewhere30. Since both involve 
rather large operations, it is obviously always necessary to compare the responses in these to 
sham-operated animals, in order to be able to exclude the effects of the operation itself. 
Banding of the aorta is achieved rather quickly compared to the natural development of an 
aortic stenosis, which the procedure is intended to imitate, while ligation of the left coronary 
artery is more comparable to an acute infarction with regard to time-course. However, it may 
be argued that the pathogenesis is not analogue to that of atherosclerotic coronary disease and 
MI in humans, given that the mice have healthy coronary arteries. Nevertheless, the coronary 
artery ligation and aortic banding models have been shown to be valid models for 
investigating post-infarction myocardial remodeling and concentric myocardial hypertrophy, 
respectively31.  
The secondary operations performed in this thesis are also described elsewhere32, 33, 
and these often included left ventricular catheterization. During this procedure a 1.4 F catheter 
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was used to measure hemodynamic parameters. Due to the small proportions in mice, even a 
catheter of this delicate size occludes a substantial part of the aorta, thus increasing afterload 
acutely. However, since we used the same method in all groups of animals examined, we 
believe that the observed differences reflect the relative in vivo differences. 
 
Echocardiography 
Echocardiography is a non-invasive method that can give serial and detailed information 
about in vivo cardiac function. The method is described in detail in Paper II. 
Echocardiography is widely used in humans, but only recently in mice. In mice the high heart 
rate and short working distance represent a technical challenge. We used a fully digital system 
with modified software that allowed sufficient time resolution for reliable end-systolic and -
diastolic measurements. A 13-MHz linear array transducer designed for the examination of 
small rodents was also used, giving a sufficiently short working distance. 
As echocardiography is both examiner- and interpreter-dependent, echocardiographic 
measurements were analyzed by two persons blinded for the intervention carried out, to assess 
interscorer reliability. Intrascorer reliability was also assessed. 
 
Measurement of infarct area 
In addition to measuring infarct size echocardiographically in Paper II, infarct area was 
measured after excision of the heart. The endocardium was unfolded and photographed with a 
digital camera. Total endocardial area and infarcted area were then traced, and infarct size as 
percentage of total area was calculated using Image J 1.32j software. The free-hand tracing of 
the different areas represented a challenge with regard to exactness, but on the other hand the 
demarcation between infarcted and non-infarcted areas was relatively easy to identify. Our 
results showed good correlation with echocardiographic findings, indicating reliability of both 
methods. 
 
Histology and immunohistochemistry 
When interpreting histological and immunohistolgical sections one has to take into account 
that these methods are only semiquatitative, and interpreter-dependent. Cutting sections as 
thin as 5 m is fraught with pitfalls, including folding of the sections, tearing of thin 
structures and making lines and distortions due to uneven or blunt knifes. The methods used 
for fixation, staining and antibody incubation, can all distort the morphology and organization 
of the tissue examined to a certain degree. Staining of sections can be uneven. Finally, the 
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antibodies used for immunohistochemistry can be of varying quality with regard to specificity 
and avidity. Our samples were interpreted by two experienced pathologists who were blinded 
for genotype and intervention. 
 
Transmission electron microscopy 
Obtaining correct and comparable fiber orientation is essential when performing transmission 
electron microscopy on cardiac tissue. Considering the minute dimensions, slicing of sections 
is a considerable challenge. The correct interpretation of findings is dependent on 
considerable experience and knowledge within the field. In our case two experienced electron 
microscopists interpreted the findings. 
 
Array screening 
The cDNA filter array strategy provides an efficient means of simultaneously analyzing a 
large number of RNA transcripts and is most helpful as a hypothesis generating tool. Apart 
from ensuring optimal technical conditions, it is imperative to make sufficient repeated 
comparisons when performing the screening. Furthermore, it is essential to have stringent 
criteria for defining genes as differentially expressed in order to be able to make deductions. 
Last but not least, it is necessary to confirm the findings by other means like PCR or Northern 
blotting. In Paper I where we used array screening, we were able to confirm all up-regulated 
genes tested, by means of Northern blotting. 
 
RT-qPCR 
Real-time RT-qPCR has emerged as the method of choice for gene expression analyses, and 
as it is highly sensitive, represents a convenient method especially when the amount of RNA 
is limited. As for all methods that require isolation of RNA it is very important to avoid 
degradation of the material by immediate snap freezing, as well as avoiding repeated freezing 
and thawing cycles. Treatment of the material with DNase is necessary in order to avoid DNA 
giving false signals in the assay. Likewise, varying quality of the RNA obtained can result in 
false differences in observed amount of PCR product. In our experiments the RNA quality 
was evaluated using bioanalyzer (Agilent) producing a RIN value (RNA Integrity Number). 
In order for the RT-PCR method to be quantitative, it is essential to use exact same input of 
total RNA for each sample when performing the reversed transcription into cDNA, otherwise 
the efficiency of cDNA synthesis has to be verified using a standard curve. It is also necessary 
to know that the efficiency of the RT-PCR reaction is constant at different concentrations. The 
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accumulation of PCR-product was monitored for each cycle using fluorescent probes 
(TaqMan), assuring that data were collected in the exponential phase of the amplification, 
which is necessary for high reproducibility as well as for obtaining quantitative results. The 
specificity of the primers and probes used is naturally also of great importance. In our 
experiments we used primers and probes with high specificity, and for comparisons of results 
obtained from different 96 well plates we made sure to normalize against an endogenous 
control (RpL4), which was run on the same plate at the same time. RpL4 is previously shown 
not to be regulated in heart failure.   
 
Northern and Western techniques 
As mentioned above, all steps must be taken to avoid degradation of the material before 
isolation of either mRNA or protein. When measuring degree of phosphorylation of different 
proteins by means of Western blots, prolonged storage of the material should be avoided as 
this can cause dephosphorylation in itself. Moreover, using antibodies and probes with highest 
possible specificity increases the chances of obtaining correct results. When several samples 
from  different groups are compared using Western, it is very important to perform a loading 
control, for example by staining the membranes with Coomassie blue, in order to be able to 
correct for uneven loading on the gel, or transmittance of protein to the membrane. In the 
cases where the samples are so many that they have to be run on two different gels, it is 
essential to have common samples on both gels enabling normalization between the two. 
 
Cultured neonatal cardiomyocytes  
Neonatal ventricular cardiomyocytes from mice were isolated as described by Masahiko 
Hoshijima, University of California, San Diego, USA, and the method is described in some 
detail in Paper III. The cardiomyocyte cell cultures were found to have a purity of 92% as 
determined by staining of nuclei and F-actin. 
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Figure 2.  Neonatal cardiac fibroblasts and cardiomyocytes. Electron micrograph of cultured neonatal 
fibroblasts (left panel) showing their typical spindle-shape and faintly visible nuclei, and of cardiomyocytes 
(right panel) showing more rounded cells with prominent nuclei and abundant fibrillar cytosolic structures. 
 
 
Neonatal cardiomyocytes are the most commonly used cells for in vitro studies of 
cardiomyocytes, mainly because they are easier to culture and have the potential to grow. 
Adult cardiomyocytes are larger, grow more slowly in vitro and have a limited potential for 
differentiation. In vivo the cardiomyocytes subjected to pathological stimuli are terminally 
differentiated, and therefore one could argue that adult cardiomyocytes are a more accurate 
model. However, both types of cells react to hypertrophic stimuli with characteristic changes 
in gene expression. So although the model has some limitations, neonatal cardiomyocytes 
represent a useful tool for studying the effects of potential pathological stimuli, like different 
cytokines or electrical pacing, in vitro. 
With regard to species, rat cardiomyocytes are substantially easier to isolate and 
culture, compared to murine. However, the study of cardiomyocytes from genetically 
modified animals necessitates the use of murine cells.  
 
Overlay techniques 
Overlay is a useful method for detecting binding between proteins in vitro. As peptide 
sequences are synthesized on membranes, the method only allows for detection of linear 
bindings, not bindings requiring a certain tertiary conformation or oligomerization. Another 
weakness of the method is false positive results resulting from overloading of the membranes, 
giving non-specific binding. 
 
Pull down techniques 
This is another in vitro method for detecting binding between proteins. Contrary to overlays, 
this technique allows for oligomerization of the proteins, as peptide sequences are bound to 
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beads instead of membranes. Therefore, pull down experiments are potentially able to detect 
more protein–protein interaction than overlays. 
 
Peptide synthesis and use of blocking peptides 
Peptides have previously been shown to become cell-permeable by coupling eleven arginine 
recidues to the N terminus34, enabling blockage of intracellular molecule interactions. 
However, dose and time needed for maximum effect may wary widely from peptide to 
peptide, and between different types of cells. In Paper III these aspects were not studied 
specifically, and chosen dose and incubation time was based on a previous study where T-
cells were incubated with a high-affinity PKA binding peptide35.  Therefore, there is no 
guarantee that we achieved maximum degree of blockage, but at least differences between 
groups were detected. It is not possible to exclude that the arginine residues added to the 
peptide have effects in their own right. For this reason scrambled peptides containing the 
same arginine residues were used as controls. Finally, it is possible that intentionally blocking 
one interaction might lead to novel interactions and effects, not occurring in untreated cells. If 
so, one would end up studying the effects of resulting new interactions, rather than the 
intended inhibition of an interaction. However, having found increased levels of pNFAT both 
in syndecan-4-/- mice subjected to AB and in WT cardiomyocytes treated with blocking 
peptides, we feel decreases the likelihood of this in our case.   
 
Generation of genetically modified mice 
It is outside the scope of this thesis to discuss the technical details and considerations that are 
important in generating genetically modified mice. However, this is reviewed by Williams et 
al36. One general consideration worth mentioning, is the importance of the genetic 
background on which the genetic modification is carried out, as the same mutation can cause 
different phenotypes in mice with different genetic backgrounds. In other words it is 
imperative to have considerable knowledge about the genetic background of the mice used for 
genetic modification, to ensure that they do not have undesirable traits with regard to the 
focus of interest. It is also important to compare these animals to wild-type animals of the 
same background. 
 
Measuring Ca2+ ATPase content 
The assay used in Paper IV for measuring Ca2+ ATPase content in homogenates measures all 
covalently bound ATP. The homogenates were therefore lysated with lye to exclude the 
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contribution of the Na-K ATPase, and identify the contribution of SERCA2. It is worth 
mentioning that this procedure does not exclude the contribution of the PMCA, but that its 
contribution is considered to be minor. Finally, the severely reduced content of Ca2+ ATPase 
measured in the SERCA2 KO animals, would be expected to challenge the assay’s ability to 
distinguish the real Ca2+ ATPase content from background, rendering these results somewhat 
inexact. However, this gives no reason to question that the content of Ca2+ ATPase found in 
the SERCA2 KO animals was severely reduced. 
 
Cardiomyocyte contraction measurements 
Cardiomyocyte contraction measurements were performed with the method described in 
Paper IV, using a video camera coupled with a video edge detector.  The cells contracted 
isotonically without external resistance against movement during these measurements. The 
conditions did therefore not completely resemble the in vivo situation where there is a 
combination of isometric and isotonic contraction. However, unloaded cell shortening 
measurements are widely used as a valid measure of cell contractile function37.  
 
Ca2+ imaging 
In Paper IV calcium transients were detected by confocal fluorescence imaging. The 
contribution of sarcoplasmic reticulum (SR) function to the size of the Ca2+ transient was 
calculated as the decrease in Ca2+ transient magnitude upon application of caffeine (the 
caffeine-sensitive component of the transient), and the SR Ca2+ content was estimated by the 
magnitude of the caffeine-induced transient. It is worth mentioning however, that these 
calculations do not take into account the possibility that the cells contain other caffeine 
sensitive compartments.  
 
Voltage clamp technique 
The voltage clamp technique was used to measure L-type Ca2+ and Na+-Ca2+ -exchanger 
(NCX) currents in Paper IV, where the method is described in some detail. Pipettes were 
introduced into the cardiomyocytes, the membrane potential was tightly controlled and the 
currents from the ionic channels were identified by use of drugs and manipulation of the 
superfusing solutions. A SR Ca2+ loading procedure was always performed first. And since 
this in itself affects the amount of Ca2+ loaded into SR, and therefore the currents released, 
this procedure was standardized as much as possible. Patch electrodes (pipettes) with 3-5 M 
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resistance were used. This gives fast voltage control, but on the other hand dialysis of cell 
constituents out of the cell, which can influence excitation-contraction coupling. 
A discontinuous voltage clamp technique was used, in which an amplifier switches 
between injecting the current needed to reach the test-potential and measuring the actual 
membrane potential at the tip of the pipette. This method allows accurate control of 
membrane potential and enables measurements of rise time and actual voltage off-line. This 
method is however slower than the continuous clamp technique. 
 
In vivo electrocardiogram recordings 
Electrocardiogram recording were carried out on mice for measurement of the Q-T interval in 
Paper IV. During the procedure the animals were only lightly anesthetized with 2% isoflurane 
via a mask in order to achieve as close to physiological conditions as possible. In addition, 
rate-corrected Q-T values were calculated to minimize the effect of a potential difference in 
heart rate response in the two genotypes  
Another challenge was to minimize the noise on the recordings, enabling exact 
determination of the Q-T interval. Satisfactory quality was achieved by replacing the 
electrodes, shaving the animal for optimal contact between animal and electrode, the use of 
earthing and turning off all nearby electrical apparatus. In addition, the average of 10 
consecutive complexes was calculated, also in order to account for variation due to 
respiration.  
 
In vivo isoproterenol infusion 
Isoproterenol infusion via the left femoral vein was carried out in Paper IV in order to 
examine the cardiac response to -adrenergic stimulation. Isoproterenol is a very potent drug 
and the doses given were miniscule, necessitating the use of a highly accurate micro-infusion 
pump. Intravascular localization of the catheter was confirmed by aspiration of blood into the 
catheter. As these experiments would last up to 90 minutes, it was obviously very important to 
control and maintain a physiological body temperature, and minimize fluid loss from the 
animal. Furthermore, anesthetic agents had to be carefully chosen in order to achieve minimal 
cardiac depression and avoid blunting of the -adrenergic response. Isoflurane is known to 
blunt the -adrenergic response, and therefore we had to choose other agents for these 
experiments.     
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Discussion 
Animal-models of human heart disease  
The amount and type of cardiac research that can be performed on humans is for obvious 
reasons limited, especially with regard to studies on myocardial tissue. Therefore one has had 
to resort to animals. The species used to create CHF depends on ethical and economic 
considerations, accessibility and reproducibility of the model, as well as the scientific 
question studied. The model should mimic the clinical setting of heart failure as closely as 
possible in order to study pathophysiological processes, while this may be less important 
when a defined causal connection is under investigation. There is no ideal animal model that 
both perfectly imitates human heart failure and is technically feasible in the laboratory. Many 
protocols have a sudden onset of heart failure, whereas human heart failure will usually 
develop over years. In humans heart failure is often associated with atherosclerosis, obesity, 
diabetes or hypertension, while this is usually not present in the animal models. Furthermore, 
most models use young adult animals, whereas heart failure in humans frequently is a disease 
of the elderly. Finally, one must not forget that simple variations in animal handling and 
housing procedures, such as cage density, diet, strain, gender, as well as site, timing and type 
of anesthesia used during operative procedures have been shown to profoundly affect 
biochemical, hematological and endocrine/metabolic parameters38.  
 Previously, a large number of studies were performed in animals with overt clinical 
heart failure, and this yielded a lot of information on hemodynamics, neurohormonal 
activation, myocardial function and molecular alterations in the failing heart39. However, with 
recent invasive and non-invasive technologies hemodynamics can be studied in patients. 
Furthermore, cardiac transplantation surgery has made end-stage failing human myocardium 
available for functional, biochemical and molecular biology studies. On the other hand, it is 
still rather difficult to study myocardial changes during compensated heart failure, the 
transition from hypertrophy to failure and during the process of remodeling. For this purpose 
animal models are still critically important. 
Traditionally the pig has been avidly used in heart research, as it is said to have the 
heart most comparable to humans. However, the pig is not very well suited for genetic 
modification, mainly because the whole genome is still not sequenced, but also because it is 
relatively expensive to keep, has a long gestation period and produces few offspring. Mice on 
the other hand, have a completely mapped genome, are cheap and easily bred into large 
numbers, and also have strong developmental, physiological and biochemical similarities with 
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humans. Ninety-nine percent of the mouse genome is homolog to the human genome. For 
these reasons, and also because of the flexibility by which informative mutations can be 
generated in almost any mouse gene, the mouse has quickly become the most used model in 
biomedical research. A major disadvantage with the mouse in relation to cardiac research 
however, is its small size. This represents a challenge when doing hemodynamic 
measurements, and also with regard to the small amounts of material obtainable for further 
analysis. 
Advances in transgene and gene targeting technology have provided important insight 
into the molecular mechanisms underlying cardiac physiology and pathophysiology. Murine 
models have been engineered harboring gene mutations leading to phenotypes reminiscent of 
human clinical disease states including congenital heart defects, cardiomyopathies and cardiac 
conduction defects (for an overview see Refs.40-42). In order to understand the relationship 
between genes, proteins and functional alterations, and to establish models in which the 
pathogenic processes can be studied longitudinally, it is necessary to direct the heart to delete 
or synthesize the candidate protein stably, in the absence of other pleiotrophic changes. One 
can then determine whether or not the protein’s presence causes an effect directly or 
indirectly. Techniques allowing gene manipulation in a spatial- and temporal-specific manner 
enable loss of the gene of interest wherever and whenever desired with targeted DNA 
recombination via the cre-loxP system, further increasing the precision of the genetic 
manipulation. Lack of target specificity can complicate or even confound the ability to dissect 
out the direct effect of the gene on cardiac function, especially if the target gene is critical to 
the function of other organ systems. In respect to transgenesis, development of systems 
allowing the transgene expression to be turned on and then shut off again during an animal’s 
life-span, is warranted. This would offer the researchers a chance not only to observe whether 
a particular transgene can cause disease, but also whether the heart is able to recover when the 
transgene is turned off. 
 
Role of syndecan-4 in pathological hypertrophy and heart failure  
Syndecan-4 
The syndecans consists of a family of four transmembrane heparan sulphate proteoglycans 
important in cell-ECM binding43. Syndecan-4 is the only member found in cardiomyocytes44, 
and has been localized to costameres45, focal adhesions46 and Z-discs45, all of which are 
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thought to be important sites of signal transduction47-49. Moreover, syndecan-4 is a co-
receptor for several growth factors and integrins50.  
 
Syndecan-4 expression in CHF 
Several factors have been shown to regulate syndecan-4 expression. However, syndecan-4 
expression during concentric hypertrophy and CHF has so far not been examined, even 
though there are a few studies that have looked at syndecan-4 expression in the cardiovascular 
system. Others have shown that intramyocardial adenoviral PR39, a prolin/arginine-rich 
peptide, injections in a pig model of chronic myocardial ischemia increased syndecan-4 
expression, and improved the perfusion and function of ischemic myocardium, at least partly 
through angiogenesis51, 52. Shi et al. found that 1-adrenergic receptor activation increased the 
expression of syndecan-4 in cell adhesion functional assays, indicating a role for syndecan-4 
in regulating cell morphology, remodeling and signaling53. Furthermore, Zhang et al. were 
able to show that TNF- secreted by hypoxic myocytes was able to induce syndecan-4 
expression in human endothelial cells54. It has also been established that syndecan-4 
expression is rapidly induced in cultured vascular smooth muscle cells (VSMCs) in response 
to basic fibroblast growth factor (FGF-2) or serum stimulation, identifying syndecan-4 as a 
primary response gene product in VSMCs55. In addition, different types of injury, like skin 
wounds51, vascular wall injury55 and myocardial infarction44, 56 have been shown to increase 
syndecan-4 expression. And finally, Li and co-workers were able to show that subjecting 
adventitial fibroblast to a mechanical stretch protocol produced a rapid increase in syndecan-4 
expression that was accompanied by both enhanced protein shedding and disassembly of focal 
adhesions, indicating that mechanical strain tightly regulates syndecan-4 expression56. 
 
Potential mechanisms of action 
Despite many potentially important functions, the role of syndecan-4 in development of 
pathological hypertrophy and heart failure has not to our knowledge been studied before. We 
have shown (Paper III) that lack of syndecan-4 inhibits development of concentric 
hypertrophy following pressure overload, strongly indicating that syndecan-4 does indeed 
have an important role.  
 26
  
Figure 3. Functions of syndecan-4. Schematic illustration of the diverse functions of syndecan-4, both extra- 
and intra-cellularly. Used with permission.  
 
The function as co-receptor for growth factors like FGF-257, vascular endothelial 
growth factor (VEGF)58 and hepatocyte growth factor (HGF)59 could potentially be important 
in this setting. FGF-2 is known to be essential for the manifestation of overload- and 
angiotensin-induced cardiac hypertrophy60, 61, and likewise, FGF-2 released by paced 
cardiomyocytes was found necessary for the hypertrophic response. The endothelial cell 
mitogen VEGF has an essential role in vasculogenesis and angiogenesis62. VEGF blockade 
has been found to result in reduced myocardial capillary density, accelerated contractile 
dysfunction and pathological cardiac remodeling63. The pluripotent growth factor HGF has 
potent angiogenic and anti-apoptotic functions64, 65. In accordance with this, blocking 
endogenous HGF worsened cardiac failure and increased mortality in a rat model of ischemic 
injury66, while HGF gene transfer following a large MI resulted in significantly preserved 
myocardial function and geometry, was associated with significant angiogenesis and a 
reduction in apoptosis67.  
 The cytoplasmic domain of syndecan-4 has been shown to regulate various 
intracellular signaling pathways. Previous studies have shown that syndecan-4 binds to and 
68, which itself has 
been shown to regulate cardiac contractility and propensity towards heart failure69. Our study 
demonstrated that lack of syndecan-4 specifically inhibited the pro-hypertrophic calcineurin-
NFAT pathway during pressure overload in mice, and that it inhibited development of 
concentric hypertrophy. This is a previously unknown and potentially very important effect of 
syndecan-4, as there is considerable evidence that the calcineurin-NFAT pathway plays an 
important role in development of pathological, but not physiological, hypertrophy70-72. 
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Potential effect of syndecan-4 on the regulation of the calcineurin-NFAT pathway 
Twenty-four hours after aortic banding syndecan-4-/- mice showed significantly higher levels 
of pNFATc4 and decreased activity of calcineurin, strongly indicating decreased activity of 
this pathway. We postulated that syndecan-4 binds and activates calcineurin. This hypothesis 
was based on our findings, together with the knowledge that syndecan-4 is known to bind and 
activate PKC- and that PKC-  activity is increased upon activation of the calcineurin-NFAT 
pathway14. The unique ability of syndecan-4 to activate PKC- in the absence of Ca2+ was 
first demonstrated by Oh et al., who also showed a requirement for phosphatidylinositolo-4,5-
biphosphate (PIP2)73.Activation of PKC- depends on the phosporylation status of Ser179 in 
the cytoplasmic domain of syndecan-4, because phosphorylation of Ser179 decreases the 
affinity for PIP2. Interestingly, Ser179 is dephosphorylated by an as yet unknown serine 
phosphatase74, which could potentially be calcineurin. Furthermore, phosphorylation of 
Ser179 has been shown to cause a conformational change near the C2 region of syndecan-4 
that ablates an interaction site with the PDZ domain of several proteins75. The PDZ domain of 
CASK can bind to the C2 region of syndecans, and coincidently binds the known calcineurin 
activator calmodulin76. Therefore we hypothesized that a direct interaction between 
calcineurin and syndecan-4 results in dephosphorylation of Ser179 causing the 
conformational change in C2 needed for the binding of CASK and calmodulin, ultimately 
leading to the activation of calcineurin by bringing calcineurin and calmodulin in close 
proximity. 
 
 
Figure 4. Hypothesized interaction between syndecan-4 and calcineurin/PP2B.  Calcineurin 
dephosphorylates Ser179 in the V region of syndecan-4, allowing CASK and calmodulin (CaM) to bind to the 
C2 region of syndecan-4, thereby facilitating the activation of calcineurin by bringing calcineurin and CaM in 
close proximity. 
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In accordance with our hypothesis we were able to show an association between 
syndecan-4 and calcineurin, by means of pull-down experiments. Furthermore we mapped the 
calcineurin A binding domain to the V-region of syndecan-4, and the syndecan-4 binding 
domain to the autoinhibitory domain in calcineurin A. Finally, we created a cell-permeable 
syndecan-4 derived peptide which was able to inhibit the calcineurin-NFAT pathway and 
increase the phosphorylation level of NFAT. Upon pull-down experiments calmodulin was 
not pulled down with the syndecan-4 peptides, contradicting a direct interaction between the 
two, and further supporting our hypothesis.  
 
Syndecan-4 as a new target for therapy 
Our results indicate benefits from inhibiting the actions of syndecan-4 at some point during 
pressure overload. We found that inhibiting development of concentric hypertrophy from the 
beginning was detrimental to cardiac function. However, halting the development of further 
pathological hypertrophy could be beneficial at a later time-point, implying the benefits of 
time-specific inhibition of syndecan-4.  
A sophisticated way of achieving time-specific inhibition of syndecan-4 in the future 
could hypothetically be the use of siRNA technology. This gene silencing technology is based 
on the use of sequence-specific short interfering RNA which have been found to form an 
RNA-induced silencing complex with other cellular proteins, resulting in selective 
degradation of the complementary single-stranded target RNA in a sequence specific manner. 
In vivo delivery of siRNA can either be carried out locally or systematically. Systemic 
delivery would have the disadvantage of affecting syndecan-4 gene expression in all cells, 
while local administration to the myocardium could for obvious reasons represent a challenge. 
In general, it would seem optimal to endeavor an organ-specific inhibition, in addition 
to time specificity, in order to avoid the possible side effects of inhibiting the actions of 
syndecan-4 in all cells. For instance lack of syndecan-4 has been shown to decrease the rate of 
wound healing77 and increase mortality following lipopolysaccharide induced sepsis78.  
 With regard to inhibiting the fore mentioned known and postulated intracellular 
functions of syndecan-4, a major challenge would be to develop a therapeutic strategy able to 
access the cytoplasmic tail of syndecan-4. The use of a peptide disruptor represents a future 
possibility in this respect. This technology is based on development of peptides able to 
penetrate cells and bind to the binding sequence of interest with higher affinity than any other 
ligand, resulting in delineation of the mediated intracellular signalling35. In our case, 
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disruption of the calcineurin binding motif on syndecan-4 should inhibit the calcineurin-
NFAT pathway and be cardioprotective. 
 
Role of SERCA2 in heart failure       
Muscle contraction is initiated when Ca2+ enters the cell via the L-Type Ca2+ channels in the 
sarcolemma and triggers the release of large amounts of Ca2+ from the SR via the ryanodine 
receptor79, 80. The concentration of cytosolic Ca2+ determines the extent of muscle activation 
and thus force generation. SERCA pumps Ca2+ back into the SR and is therefore responsible 
for muscle relaxation and replenishing Ca2+ stores needed for the next contraction81. SERCA 
activity is regulated by PLB, which in its unphosphorylated state lowers the affinity of 
SERCA for Ca2+82. Ca2+ removal by the NCX in the sarcolemma also contributes to 
maintenance of intracellular Ca2+ homeostasis83. 
 
Figure 5. Schematic representation of Ca2+ homeostasis in cardiomyocytes. RyR, ryanodin receptor; TNT, 
troponin T; TNC, troponin C; TNI, troponin I; ATP reflects energy consumption of SERCA; PL, 
phospholamban; NCX, sodium-calcium exchanger; SERCA, Sarco(endo)plasmatic reticulum Ca2+ ATPase. 
Modified from 8 and used with permission. 
  
Abnormalities commonly seen in CHF include a negative force-frequency relationship 
associated with disturbed Ca2+ handling84, 85 characterized by increased diastolic Ca2+ content, 
reduced SR Ca2+ content and increased duration and reduced amplitude of Ca2+ transients. 
Several studies suggest that down-regulation of SERCA activity underlies these 
abnormalities, possibly in combination with increased NCX activity. A promising approach to 
restoring functional abnormalities found in CHF could therefore be adenoviral gene therapy to 
compensate for decreased SERCA synthesis. 
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 Transgenic animals with increased SERCA levels in the heart have demonstrated that 
increases in SERCA pump levels alter Ca2+ homeostasis and enhance contractile function in 
the heart86-88. Heterozygous mice with one functional allele after disruption of the SERCA2 
gene by homologous recombination on the other hand, showed a ~35% reduction in 
SERCA2a protein levels and maximal velocity of SR Ca2+ uptake89. Despite not developing 
cardiac hypertrophy or heart failure, these heterozygous mice did display moderate cardiac 
dysfunction on in vivo measurements, as well as a more than 30% decreased peak amplitude 
of Ca2+ transients in isolated myocytes, resulting in decreased rates of cell shortening and 
relengthening. 
 In our mice with cardiac specific deletion of the Serca2 gene described in Paper IV, 
function was to our surprise largely preserved after four weeks, despite them having <5% 
SERCA2 protein in the myocardium compared to the mice with no deletion. Although 
deletion of the SERCA2 gene in adult mice ultimately caused myocardial dysfunction, our 
study shows that cardiac function is well preserved for several weeks despite loss of SERCA2 
protein. The L-type Ca2+ channel current, the NCX current and the sarcolemmal Ca2+ ATPase 
protein were increased and may contribute to the enhanced non-SR dependent maintenance of 
Ca2+ transients. Thus, Ca2+ influx and efflux across the plasma membrane may represent a 
powerful mechanism for cardiomyocyte contraction that compensates for loss of SR function. 
Our data also indicate that the myofilament Ca2+ responsiveness is increased to compensate 
for the small Ca2+ transients. Taken together, our findings show that the mouse heart is able to 
deal with an extreme reduction in SERCA2 protein before any development of overt heart 
failure occurs.  
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Conclusions 
Paper I: 
There is an up-regulation of a large number of ECM-associated genes in the non-infarcted 
region following MI in the mouse. The observed up-regulation of BMP-1 may have a 
particularly important role in this context, since it processes procollagen into collagen and 
activates latent growth factors. Moreover, considering the ability of syndecan-4 to bind the 
cytoskeleton to the ECM and its role as a required receptor for FGF, the observed increase in 
syndecan-4 on both RNA and protein level, suggests a role in cardiac remodeling following 
MI. 
 
Paper II: 
Significantly increased left atrial diameter and infarct size >40% of total LV circumference 
may serve as major criteria for heart failure with congestion after MI in mice. 
 
Paper III: 
Lack of syndecan-4 inhibits both development of concentric hypertrophy and activation of the 
calcineurin-NFAT pathway in response to chronic pressure overload. Furthermore, the 
calcineurin A binding domain is located in the V-region of syndecan-4 and the syndecan-4 
binding domain in the autoinhibitory domain in calcineurin A. Finally, a cell permeable 
syndecan-4 derived peptide inhibits the calcineurin-NFAT pathway and increase the 
phosphorylation level of NFAT. 
 
Paper IV: 
In adult mice with a cardiomyocyte-specific deletion of the Serca2 gene, enhanced 
Ca2+ cycling over the plasma membrane together with increased myofilament 
responsiveness represent powerful compensatory mechanisms that largely preserve in 
vivo cardiac function. 
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Errata 
Paper III 
Page 2, line 7-8: the following part of the sentence should be deleted; “and calmodulin, a 
known calcineurin activator” 
 
Paper IV 
Page 9, line 14: the correct denomination for cell capacitance is pF. 
Page 9, line 21- page 10, line 1: reduction in peak myocardial contraction velocity was 38%, 
and reduction in peak relaxation velocity was 28% 
Page 1 in Supporting Information, line 13, 16, 19 and 20: the correct denomination for 
isoproterenol dose is ng/min/kg. 
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